Skip to content

ED50 of Pretreatment with Lidocaine for Attenuating Propofol Injection Pain in Pediatric Patients: A Clinical Trial Using Dixon’s Up-and-Down Sequential Design

ED50 of Pretreatment with Lidocaine for Attenuating Propofol Injection Pain in Pediatric Patients: A Clinical Trial Using Dixon’s Up-and-Down Sequential Design

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124874
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Propofol injection pain

Interventions

Children aged 5 to 7 years:Intravenous lidocaine pretreatment was followed 15 seconds later by a fixed dose of propofol (2.5 mg/kg)
Children aged 2 to 4 years:Intravenous lidocaine pretreatment was followed 15 seconds later by a fixed dose of propofol (2.5 mg/kg)

Sponsors

Foshan Women and Children Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1.Pediatric patients scheduled for general anesthesia at Foshan Women and Children Hospital were selected. 2.Age 2 to 7 years old, gender not limited; 3.American Society of Anesthesiologists (ASA) classification grades ? to ?; 4.Patients with Mallampati class I or II and normal development; 5.A 24-gauge intravenous cannula was placed in the dorsum of the hand. 6.The family members sign the informed consent form for the clinical trial.

Exclusion criteria

Exclusion criteria: 1.A history of allergy or contraindication to any of the study medications. 2.Patients were excluded if they had an acute upper respiratory tract infection; 3.Difficult airway; 4.Use of sedatives (such as midazolam or barbiturates), psychotropic agents, or opioids within 7 days prior to surgery. 5.A newly inserted peripheral intravenous cannula; 6.Patients were excluded if they exhibited either excessive crying/agitation that compromised anesthesia assessment or a psychiatric disorder precluding cooperation. 7.Presence of asthma, congenital heart disease, arrhythmia, or severe hematological, renal, or hepatic disease. 8.Those whom the investigator deems unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Composite pain score for propofol injection pain;

Secondary

MeasureTime frame
Adverse Event;NIBP?HR?SpO2;MOAA/S score;

Countries

China

Contacts

Public ContactChen Yifei

Foshan Women and Children Hospital

591467821@qq.com+86 10 00000000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026